Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Francis McDermott, M.D.

Co-Author

This page shows the publications co-authored by David McDermott and Michael Morse.
Connection Strength

0.588
  1. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52.
    View in: PubMed
    Score: 0.170
  2. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer. 2014; 2:20.
    View in: PubMed
    Score: 0.145
  3. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J Pers Med. 2014 Mar 07; 4(1):52-64.
    View in: PubMed
    Score: 0.142
  4. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017 12 19; 5(1):102.
    View in: PubMed
    Score: 0.046
  5. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer. 2017 02; 15(1):31-41.e4.
    View in: PubMed
    Score: 0.043
  6. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.